MedTrace Logo

Video Assisted Study of Salbutamol Response in Viral Wheezing

NCT06093152 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2025-02-13

No results posted yet for this study

Summary

The study is video assisted cross-over study evaluating the effect of inhaled salbutamol in wheeze in children 6-24 months old.

Conditions

  • Wheezing

Interventions

DRUG

Salbutamol

Inhaled salbutamol (SABA, selective beta2-adrenergic receptor agonist) 0,1 mg 4-6 puffs 3-4 times every 20 minutes administered by OptiChamber holding chamber.

Sponsors & Collaborators

  • University of Oulu

    lead OTHER

Principal Investigators

  • Terhi Tapiainen, Professor · University of Oulu

Eligibility

Min Age
6 Months
Max Age
24 Months
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-23
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • Finland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06093152 on ClinicalTrials.gov